Varghese Sherin, Jisha M S, Rajeshkumar K C, Gajbhiye Virendra, Alrefaei Abdulwahed Fahad, Jeewon Rajesh
School of Biosciences, Mahatma Gandhi University, Kottayam, Kerala, 686560, India.
National Fungal Culture Collection of India (NFCCI), Biodiversity and Palaeobiology (Fungi) Gr., Agharkar Research Institute, G.G. Agharkar Road, Pune, 411 004, Maharashtra, India.
Heliyon. 2024 Jul 4;10(13):e33995. doi: 10.1016/j.heliyon.2024.e33995. eCollection 2024 Jul 15.
Globally, breast cancer is a primary contributor to cancer-related fatalities and illnesses among women. Consequently, there is a pressing need for safe and effective treatments for breast cancer. Bioactive compounds from endophytic fungi that live in symbiosis with medicinal plants have garnered significant interest in pharmaceutical research due to their extensive chemical composition and prospective medicinal attributes. This review underscores the potentiality of fungal endophytes as a promising resource for the development of innovative anticancer agents specifically tailored for breast cancer therapy. The diversity of endophytic fungi residing in medicinal plants, success stories of key endophytic bioactive metabolites tested against breast cancer and the current progress with regards to studies and clinical trials on endophytic fungal metabolites in breast cancer research forms the underlying theme of this article. A thorough compilation of putative anticancer compounds sourced from endophytic fungi that have demonstrated therapeutic potential against breast cancer, spanning the period from 1990 to 2022, has been presented. This review article also outlines the latest trends in endophyte-based drug discovery, including the use of artificial intelligence, machine learning, multi-omics approaches, and high-throughput strategies. The challenges and future prospects associated with fungal endophytes as substitutive sources for developing anticancer drugs targeting breast cancer are also being highlighted.
在全球范围内，乳腺癌是导致女性癌症相关死亡和疾病的主要因素。因此，迫切需要安全有效的乳腺癌治疗方法。与药用植物共生的内生真菌产生的生物活性化合物，因其丰富的化学成分和潜在的药用特性，在药物研究中引起了广泛关注。本综述强调了真菌内生菌作为开发专门用于乳腺癌治疗的创新抗癌药物的有前景资源的潜力。存在于药用植物中的内生真菌的多样性、针对乳腺癌测试的关键内生生物活性代谢物的成功案例，以及乳腺癌研究中内生真菌代谢物的研究和临床试验的当前进展，构成了本文的主题。本文全面汇编了1990年至2022年期间从内生真菌中提取的已证明对乳腺癌具有治疗潜力的推定抗癌化合物。这篇综述文章还概述了基于内生菌的药物发现的最新趋势，包括人工智能、机器学习、多组学方法和高通量策略的应用。同时也强调了将真菌内生菌作为开发针对乳腺癌的抗癌药物的替代来源所面临的挑战和未来前景。
